Both in Pharmaceuticals
Apimeds Pharmaceuticals US vs Xenetic Biosciences
Over the past year APUS returned −88.0% and XBIO returned −33.3%; their daily moves had a correlation of 0.06.
APUS −88.0% XBIO −33.3%Growth of $1, one year, split-adjusted
| Metric | APUS | XBIO |
|---|---|---|
| Price | $2.97 | $2.08 |
| Market cap | $4.5M | $4.9M |
| Today | +2.77% | +0.97% |
| 1 month | −35.3% | −5.5% |
| 6 months | −90.1% | −32.7% |
| Year to date | −81.9% | −4.1% |
| 1 year | — | −37.7% |
| Revenue growth (YoY) | — | +12.0% |
| Gross margin | — | 100.0% |
| Net margin | — | −140.7% |
| P/E (TTM) | — | — |
| Price / sales | — | 3.3× |
| Net cash | -$8.6M | $6.5M |
| Dividend yield | — | — |
| Volatility (60d) | 264.0% | 158.7% |
| Short % of float | 0.9% | 0.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).